THC Farmaceuticals, Inc.
CBDG · OTC
6/30/2022 | 3/31/2022 | 12/31/2021 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.30 | -0.20 | 0.00 | 0.00 |
| FCF Yield | -0.25% | -0.16% | -0.59% | -0.26% |
| EV / EBITDA | -408.08 | -278.48 | -1,951.90 | 44.67 |
| Quality | ||||
| ROIC | -0.25% | -0.44% | -0.07% | -0.65% |
| Gross Margin | 0.00% | 0.00% | 90.48% | 100.00% |
| Cash Conversion Ratio | 1.42 | 0.70 | 7.75 | -0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 834.10% | 965.17% | 1,024.64% | 860.26% |
| Free Cash Flow Growth | -12.98% | 39.32% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -70.62 | -36.10 | -449.15 | 2.93 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,838.59 | -2,838.59 | 2,887.33 | 11,154.75 |